Abstract
We examined the genetic implications and clinical impact of telomere length (TL) in 67 patients with acute myeloid leukemia (AML). There was a trend toward improved survival at 6 months in patients with longer TL. We found that patients with activating mutations, such as FLT3-ITD, had shorter TL, while those with mutations in epigenetic modifying enzymes, particularly IDH1 and IDH2, had longer TL. These are intriguing findings that warrant further investigation in larger cohorts. Our data show the potential of TL as a predictive biomarker in AML and identify genetic subsets that may be particularly vulnerable to telomere-targeted therapies.
Original language | English (US) |
---|---|
Pages (from-to) | 62-65 |
Number of pages | 4 |
Journal | Leukemia Research |
Volume | 49 |
DOIs | |
State | Published - Oct 1 2016 |
Funding
This research was supported by an American Society of Clinical Oncology (ASCO) Young Investigator Award (YIA) (recipient: Justin Watts, mentor: Martin Tallman). This work was also supported by and completed at Memorial Sloan Kettering Cancer Center and the National Heart, Lung, and Blood Institute in equal collaboration.
Keywords
- Acute myeloid leukemia
- Clinical outcomes
- Somatic mutations
- Telomere length
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research